BOD — Bod Science Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -221.02% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 6 | 7.44 | 5.09 | 3.32 | 2.86 | n/a | n/a | 16.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for consumer and medical markets. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company’s segments include medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.
Directors
- Mark Masterson NEC
- Joanne Patterson CEO
- Adrian Sturrock CFO
- Craig Weller COO
- John Gilder DSL
- Stephen Kelly SEC
- Akash Bedi NED
- Hanno Cappon NED (55)
- George Livery NED
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- August 13th, 2014
- Public Since
- October 27th, 2016
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 177,338,493
- Address
- Level 1, SYDNEY, 2028
- Web
- https://bodscience.com/
- Phone
- +61 291995018
- Auditors
- Nexia Sydney Audit Pty Limited
Upcoming Events for BOD
Similar to BOD
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:39 UTC, shares in Bod Science are trading at AU$0.02. This share price information is delayed by 15 minutes.
Shares in Bod Science last closed at AU$0.02 and the price had moved by -83.45% over the past 365 days. In terms of relative price strength the Bod Science share price has underperformed the ASX All Ordinaries Index by -84.13% over the past year.
There is no consensus recommendation for this security.
Find out moreBod Science does not currently pay a dividend.
Bod Science does not currently pay a dividend.
Bod Science does not currently pay a dividend.
To buy shares in Bod Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.02, shares in Bod Science had a market capitalisation of .
Here are the trading details for Bod Science:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BOD
Based on an overall assessment of its quality, value and momentum Bod Science is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bod Science. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -50.22%.
As of the last closing price of AU$0.02, shares in Bod Science were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bod Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bod Science's management team is headed by:
- Mark Masterson - NEC
- Joanne Patterson - CEO
- Adrian Sturrock - CFO
- Craig Weller - COO
- John Gilder - DSL
- Stephen Kelly - SEC
- Akash Bedi - NED
- Hanno Cappon - NED
- George Livery - NED